Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Undisclosed
Sponsor : GigaGen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic™ Technology
Details : Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Sponsor : GigaGen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Immunomedics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics
Details : Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Immunomedics
Deal Size : Undisclosed
Deal Type : Licensing Agreement